Article
Reduced efficacy of HIV-1 integrase inhibitors in patients with drug resistance mutations in reverse transcriptase.
Nature communications - 1 Dec 2020
Siedner Mark J, Moorhouse Michelle A, Simmons Bryony, de Oliveira Tulio, Lessells Richard, Giandhari Jennifer, Kemp Stephen A, Chimukangara Benjamin, Akpomiemie Godspower, Serenata Celicia M, Venter Willem D F, Hill Andrew, Gupta Ravindra K
Abstract excerpt
Little is known about the impact of pretreatment drug resistance (PDR) on the efficacy of second generation integrase inhibitors. We sequenced pretreatment plasma specimens from the ADVANCE trial (NCT03122262). Our primary outcome was 96-week virologic success, defined as a sustained viral load <1000 copies/mL from 12 weeks onwards, <200 copies/mL from 24 weeks onwards, and <50 copies/mL after 48 weeks. Here we...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.